TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00553748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-18 FLT
Description: One - 10 mci dose of F-18 FLT is administered IV over about 5 seconds prior to PET imaging. Each imaging dose contains no more than 6.1 micrograms of FLT.
Study: NCT01543607

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation catheter (Habib EndoHBP)
Description: Catheter placement into bile duct
Study: NCT00397839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibandronate
Description: Ibandronate orally (tablet) at a dose of 150 mg once per month

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo orally (tablet) at a dose of 150 mg once per month
Study: NCT03753373

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture treatments will be utilizing the KB-2 points with manual manipulation accomplished by vigorously running the acupuncturists thumb nail up and down the handle until a perceived sensation change is noted in the subject's posteromedial tibia. A single, sterile 100mm needle will be inserted into the upper third of the medial tibiofibular ligament, followed by a second needle approximately 2-4 cm below the second needle. The needles will be manipulated as detailed above to achieve the sensation change along the posteromedial tibia. The needles will then be irregularly stimulated over the course of 5-7 minutes. The needles will be removed after the treatment is complete, which will last approximately 5-10 minutes (standard care).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home Exercise Program
Description: Subjects will be given a study diary to document the number of times they performed the standard of care prescribed home exercise program. Subjects will be advised to complete the stretching exercises daily and the strengthening exercises every other day.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home Exercise Program
Description: Subjects will be given a study diary to document the number of times they performed the standard of care prescribed home exercise program. Subjects will be advised to complete the stretching exercises daily and the strengthening exercises every other day.
Study: NCT00614458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir; valproic acid
Description: raltegravir 400mg po BID; valproic acid 1000mg - 2000mg daily
Study: NCT02899052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib lyophilized administered intravenously as a 10 to 30 minute infusion in Cycles 1 and beyond within 30 minutes to 4 hours after dexamethasone dosing.~Dose level 1 (K1) Cycle 1: 20 mg/m2 on Days 1 and 2, 27 mg/m2 on Days 8, 9, 15, and 16; Cycles 2 - 12: 27 mg/m2 on Days 1, 2, 8, 9, 15, and 16; Cycles 13 - 18: 27 mg/m2 on Days 1, 2, 15, and 16; Cycles 19 and beyond, for participants that have not previously transitioned to monotherapy: 27 mg/m2 on Days 1, 2, 15, and 16.~Dose Level K2: Cycle 1: 20 mg/m2 on Day 1; 70 mg/m2 on Days 8 and 15 Cycles 2 - onward: 70 mg/m2 on Days 1, 8, and 15. Dose Level K3: Cycle 1: 20 mg/m2 on Days 1 and 2; 56 mg/m2 on Days 8, 9, 15, and 16.~Cycles 2 - onward: 56 mg/m2 on Days 1, 2, 8, 9, 15, and 16.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax tablet administered orally once daily during Cycles 1 - onward. Venetoclax dose level 1 (Ven1) 400 mg once daily, Ven2 800 mg once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone tablet administered orally during Cycles 1 - onward. Dexamethasone dose level 1 (Dex1) 40 mg once weekly, Dex2 40 mg once weekly, Dex3 20 mg twice weekly.
Study: NCT02118207

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic running exercise
Description: 60 min of aerobic intervals completed prior to SCUBA diving

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic running exercise
Description: 60 min of aerobic intervals completed prior to SCUBA diving
Study: NCT01953627

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical procedure with the system Kymerax

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The system Kymerax
Study: NCT00568152

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low PA apple puree
Description: Golden Delicious apple puree 230grams consumed daily for 14 days

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High PA apple puree
Description: High PA apple puree (Mitchalin) consumed daily for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin
Description: 75mg dispersable aspirin taken daily for 14 days
Study: NCT02509520

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: MPR and High Protein Supplement (HPRO) and Neuromuscular Electric Stimulation (NMES)
Description: The MPR provides strength and cardiopulmonary endurance training, which consist of exercises to promote function movements. Intensity is based on patient's hemodynamic responses and subjective report using Modified Borg Dyspnea Scale. Intensity, duration, or type of activity will be modified each session to achieve a moderately intense physiologic response. The NMES protocol requires self-adhesive surface electrodes be placed on quadriceps muscles and lower leg bilaterally, twice daily. This protocol is based on prior NMES protocols used to stimulate muscle protein synthesis in older diabetic patients, preserve muscle mass in intensive care patients and increase strength in older adults after knee replacement. The HPRO intervention is based on caloric needs, calculated using validated equations to maintain positive nitrogen balance. Protein will be supplemented as isolated amino acids twice/day to deliver \~15g of essential amino acids per serving, with a goal of 1.6 g/kg/day.
Study: NCT01375569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRC105
Study: NCT03125824

Intervention type: DEVICE
Group type: OTHER
Intervention: Soliton Acoustic Wave Device
Description: Treatment of tattoos with Soliton Acoustic Wave Device as an accessory to laser
Study: NCT02496221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albiglutide 50 mg
Description: Albiglutide 50 mg pen is a single-use fixed dose, fully disposable pen injector system for SC delivery in the abdomen containing 67 mg lyophilized albiglutide and 0.65 mL diluents designed to deliver a dose of 50 mg in a volume of 0.5 mL after reconstitution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is a single-use fixed dose, fully disposable pen injector system for SC delivery of 0.5 mL injector volume in the abdomen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCK (Kinevac)
Description: CCK (Kinevac) will be infused intravenously. Kinevac is supplied in vials containing 5 microgram (mcg)/vial. Infusion prepared aseptically by adding 5 mL of Sterile Water for Injection United States Pharmacopeia (USP) to the vial to create a solution of 1 mcg/mL. Infuse 0.003 mcg/kg dose in 100 mL of Sodium Chloride Injection USP, 0.9%
Study: NCT02226939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BILN 2061 ZW

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02023788

Intervention type: BIOLOGICAL
Intervention: PNEUMOSTEM
Description: A single intratracheal administration~Low Dose Group (3 patients): 1.0 x 10\^7 cells/kg High Dose Group (6 patients): 2.0 x 10\^7 cells/kg~\* The subjects were administered with Pneumostem in the earlier part of the Phase I study. No drug/biologics will be administered to any subject during this part of the study.
Study: NCT01586767

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Proton radiation therapy
Description: Daily proton radiation therapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intensity-modulated radiotherapy
Description: Daily intensity-modulated radiotherapy
Study: NCT01514656

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CPR Training using the Family and Friends CPR Anytime Video Self Instruction
Description: Subjects will be trained using the American Heart Association's Family and Friends CPR Anytime Program. The subject's will undergo training in-hospital then they will be encouraged to take the training materials home with them to practice CPR with their family members and friends.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CPR Training using the Family and Friends CPR Anytime Video Self Instruction
Description: Subjects will be trained using the American Heart Association's Family and Friends CPR Anytime Program. The subject's will undergo training in-hospital then they will be encouraged to take the training materials home with them to practice CPR with their family members and friends.
Study: NCT03812458

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: website and brochure
Description: website and brochure
Study: NCT02964845

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WISH with CHW and referral to HFM
Description: 6 intervention counseling sessions with a peer CHW, as well as CHW facilitated linkage to primary care and HIV risk reduction.

Intervention type: OTHER
Group type: OTHER
Intervention: Enhanced Treatment as Usual
Description: Linkage to Primary care.
Study: NCT02015897

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physical TherapyA
Description: Group A:~* Skin care~* Manual lymphatic drainage~* Bandaging using Coban™2Lite~* Guidance on physical activity

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Physical TherapyB
Description: Group B:~* Skin care~* Bandaging using Coban™2Lite~* Guidance on physical activity
Study: NCT02796339

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Mastiha

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01514656

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Implementation of a Hospital-based CPR Training Model
Description: Nurses and Volunteers will be trained in the hospital-based CPR Training Model, and be encouraged to implement the training program in their respective hospitals.
Study: NCT03178552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Participants will receive 15 mg/kg of IV bevacizumab on Day 1 of each 21-day cycle during the induction and maintenance periods.
Study: NCT01514656

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Implementation of a Hospital-based CPR Training Model
Description: Nurses and Volunteers will be trained in the hospital-based CPR Training Model, and be encouraged to implement the training program in their respective hospitals.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Follow-up prompting to encourage skill retention
Description: Subjects will be contacted every two months and encouraged to practice the skills that they have learned. Means of contact include: a) email b) text blasts c) phone calls d) social media e) mail

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Follow-up prompting to encourage skill retention
Description: Subjects will be contacted every two months and encouraged to practice the skills that they have learned. Means of contact include: a) email b) text blasts c) phone calls d) social media e) mail
Study: NCT03330197

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad-RTS-hIL-12
Description: 2.0 x 10\^11 viral particles (vp) per injection, one intratumoral injection of Ad-RTS-hIL-12

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad-RTS-hIL-12
Description: 2.0 x 10\^11 viral particles (vp) per injection, one intratumoral injection of Ad-RTS-hIL-12

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Veledimex - Arm 1 (Pediatric Brain Tumor)
Description: 1 dose level (10mg/day) 15 oral daily doses of veledimex

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Veledimex - Arm 2 (DIPG)
Description: 2 dose levels (10mg/day, 20mg/day) 14 oral daily doses of veledimex
Study: NCT02659488

Intervention type: DRUG
Group type: OTHER
Intervention: Lisdexamfetamine
Description: 20 healthy controls and 20 women subjects with BED agreeing to a 12-week, open-label trial of LDX and fMRI assessments immediately before and after the 12 weeks of LDX treatment will be recruited
Study: NCT04343989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clazakizumab 25 mg
Description: The first dose will be administered as soon as possible after the patient is enrolled and randomized into the Clazakizumab 25 mg arm. The route of administration will be intravenous. Each dose will be administered as an infusion that is run over 30 minutes. Serum CRP will be evaluated at baseline and on days 1 and 2 following clazakizumab administration. If the CRP does not decrease by 50% within 36-48 hours after the first dose, a second dose of 25 mg clazakizumab will be given no later than day 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clazakizumab 12.5 mg
Description: The first dose will be administered as soon as possible after the patient is enrolled and randomized into the Clazakizumab 12.5 mg arm. The route of administration will be intravenous. Each dose will be administered as an infusion that is run over 30 minutes. Serum CRP will be evaluated at baseline and on days 1 and 2 following clazakizumab administration. If the CRP does not decrease by 50% within 36-48 hours after the first dose, a second dose of 12.5 mg clazakizumab will be given no later than day 3.
Study: NCT04618952

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium D
Description: calcium D supplementation given to postmenopausal females

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01327638

Intervention type: DRUG
Intervention: etoricoxib
Description: Patients with SpA/AS who took etoricoxib

Intervention type: DRUG
Intervention: Other COX-2 inhibitor
Description: Patients with SpA/AS who took other COX-2 inhibitors

Intervention type: DRUG
Intervention: nsNSAIDs
Description: Patients with SpA/AS who took nsNSAIDs
Study: NCT04455594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Almonertinib
Description: Oral, 110mg QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erlotinib
Description: Oral, 150mg QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin(75mg/m2) be administered with pemetrexed (500mg/m2) on Day 1 of every 3-week cycle for 3 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin (AUC=5) to be administered with pemetrexed (500mg/m2) on Day 1 of every 3-week cycle for 3 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed (500mg/m2) to be administered with Cisplatin(75mg/m2) or Carboplatin (AUC=5) on Day 1 of every 3-week cycle for 3 cycles
Study: NCT01559831

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: IXIARO
Description: Vero-cell derived Japanese encephalitis (JE) vaccine IXIARO, 0.5 ml intramuscular
Study: NCT04891367

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy
Description: The G-CBT manual for adolescents has been developed in the OCD-clinic in Aarhus and pilot tested in Aarhus. The G-CBT manual is based on the NordLOTS I-CBT manual in overall content and structure, with a few additional elements added with inspiration from previous individual and group CBT literature as well as the author's ideas. The main therapeutic ingredient is exposure and response prevention. The manual is made up of three individual family sessions, 13 weekly adolescent group sessions, three parent group sessions and two adolescent group booster sessions.The manual contains detailed guiding of therapists for each session and a comprehensive collection of working sheets for the adolescents to be used during sessions.
Study: NCT01358019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2523355
Description: Days 1, 2, and 3 in a cycle that consists of 21-days
Study: NCT01134588

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Paper questionnaire

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Touch screen questionnaire
Study: NCT02322242

Intervention type: DRUG
Group type: OTHER
Intervention: Systemic Dexamethasone
Description: Intravenous infusion of dexamethasone (4mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perineural dexamethasone
Description: Perinerual administration of dexamethasone (4mg)
Study: NCT03996707

Intervention type: OTHER
Group type: OTHER
Intervention: Weight Bearing
Description: Immediate protected weight bearing in a CAM walking boot following foot \& ankle surgery

Intervention type: OTHER
Group type: OTHER
Intervention: Strict non-weight bearing
Description: Strict non weight bearing for 6 weeks following foot \& ankle surgery
Study: NCT04368325

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum creatinine levels
Description: Comparison of treatment length using mechanical ventilaton, length of stay in ICU, survival between two groups

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum creatinine levels
Description: Comparison of treatment length using mechanical ventilaton, length of stay in ICU, survival between two groups
Study: NCT00891878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Description: Given orally
Study: NCT02122510

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacine group
Description: Bupivacaine group(n=30) will receive post-delivery bilateral TAP block with 10 ml of bupivacaine 0.5 % mixed with 10 ml saline and 10 μg dexmetonedine in 20 ml syringe

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexamedtomedine group will receive post-delivery bilateral TAP block with 10 ml of bupivacaine 0.5 % mixed with 10 ml saline and 10 μg dexmetonedine in 20 ml syringe
Study: NCT01291719

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: glucose and insulin infusions
Description: combined algorithm directed glucose and insulin infusion with 5 minute blood glucose measurements to direct glucose control; regular insulin and glucose are infused intravenously as adjusted by the algorithm without manual intervention in the group of diabetic individuals under study to adjust the glucose level to a target range of 80-180 mg/dl
Study: NCT03845322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin Pill
Description: Curcumin (turmeric extract), over the counter supplement (1 capsule/three times a day). According to the Company, each capsule contains: 270 mg of pure curcuminoids (curcumin) and 3 mg of black pepper extract. Recommended serving size is 3 capsules per day in total, the patients will receive 810 mg of pure curcumin and 9 mg of black pepper extract (peperine/BioPerine) per day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pills
Description: The placebo pill is a vegetarian cellulose capsule, with cellulose powder inside. The composition is cellulose and magnesium stearate.
Study: NCT03459833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid
Description: Glans penis augmentation using multiple puncture technique as described by Abdallah et al. (2012) with minor modifications. HA is injected at two circular levels: one at the level of corona of glans penis and a second circular level is mid-way between the corona and urethral meatus. Six injections are injected at coronal level and four are injected in the second level, each injection is of 0.2 ml and is injected into deep dermis.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hyaluronic Acid
Description: Glans penis augmentation using multiple puncture technique as described by Abdallah et al. (2012) with minor modifications. HA is injected at two circular levels: one at the level of corona of glans penis and a second circular level is mid-way between the corona and urethral meatus. Six injections are injected at coronal level and four are injected in the second level, each injection is of 0.2 ml and is injected into deep dermis.
Study: NCT01595074

Intervention type: OTHER
Intervention: medical chart review
Description: Correlative studies

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01127386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 25mg od, dose reduction according to toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: start with 5mg od and increase of dosage to 10mg, 15mg or 25mg until CRP response (50% decrease)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: basic cachexia management (prokinetics, physical activity counselling, nutritional counselling)
Description: twice during study
Study: NCT01542736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered concurrently with craniospinal radiation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Administered concurrently with craniospinal radiation.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 24 Gy
Description: Craniospinal radiation.
Study: NCT02038400

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: KINETUBE medical Device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: insertion of tympanic ventilation tubes (tympanostomy)
Study: NCT01644578

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Real-time imaging for MRI-guided procedures
Description: Real-time imaging for improvement of workflow in MRI-guided procedures
Study: NCT00720733

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Skills-Building Intervention
Description: A 5-week intervention including 5 weekly sessions covering 8 varied coping skills with daily home practice. The skills are: 1) noting daily positive events; 2) capitalizing on positive events; 3) gratitude; 4) mindfulness; 5) positive reappraisal; 6) focusing on personal strengths; 7) setting and working toward attainable goals; and 8) small acts of kindness. Sessions are 1 hour long and include approximately 30 minutes per day.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Personal Interview Group
Description: There are 5 weekly sessions which will be approximately one hour long and will consist of personal interview. The interviews will include both quantitative and qualitative questions. Each session will have a separate theme including: Life 1) History; 2) Health History; 3) Personality; 4) Social Networking; and, 5) Meaning \& Purpose.